— 01 · At a Glance
What is Alpha PRRT?
★ In one paragraph
Alpha PRRT uses the same DOTATATE peptide that binds somatostatin-2 receptors on neuroendocrine tumour cells — but pairs it with actinium-225, an alpha emitter, in place of the beta emitter lutetium-177. The alpha payload delivers far denser radiation over a much shorter tissue range, producing potent cell killing including against Lu-resistant tumour clones. Alpha PRRT is primarily a salvage line for patients whose NETs have progressed on standard Lu-177 DOTATATE.
The therapy is administered as an outpatient intravenous infusion every 8 to 12 weeks for 3 to 4 cycles. Each cycle is preceded by amino acid renal protection to reduce kidney radiation exposure. The total course typically spans 7 to 10 months. Like beta PRRT, eligibility starts with a 68Ga-DOTATATE PET/CT confirming strong SSTR-2 expression in the disease.
Alpha PRRT is an established but still-emerging radioligand therapy — offered worldwide at specialist theranostic centres including the original Heidelberg group, AIIMS Delhi, our department at FMRI, and a handful of others. It is delivered on a clinical compassionate use basis, with case-by-case multidisciplinary review.
— 02 · Mechanism
Why alpha works when beta no longer does.
The fundamental difference between Lu-177 and Ac-225 lies in the physics of the radiation each emits, not in the targeting molecule. DOTATATE binds SSTR-2 the same way in both. What changes is what happens after binding:
- Beta particles (Lu-177) travel approximately 2 millimetres through tissue and deliver moderate energy per micrometre. Excellent for moderate-sized disease, less effective against very small tumour foci or resistant clones.
- Alpha particles (Ac-225) travel only 50 to 100 micrometres — about the diameter of 2 to 5 cells — but with ~100 times higher linear energy transfer (LET) than beta. Each alpha strike produces dense, clustered DNA damage that the cell cannot repair.
- Repair-independent. Lu-resistant cancer cells often resist beta because their DNA repair machinery has adapted. Alpha damage overwhelms repair pathways — making it effective even in beta-refractory disease.
225Ac
ALPHA RADIATION · SHORT-RANGE, HIGH-LET
[Image: Comparison diagram — Lu-177 beta vs Ac-225 alpha tissue penetration around an SSTR-2-bound NET cell, showing alpha's short 50-100 μm range with high-density DNA damage clusters vs beta's longer 2 mm range with sparser hits]
Ac-225 itself decays through a chain of four daughter alphas, multiplying the cytotoxic dose delivered per molecule bound. This is why 100 kBq/kg of Ac-225 produces tumour effect comparable to gigabecquerel doses of Lu-177 — despite vastly lower administered activity.
— 03 · Side by Side
Lu-177 DOTATATE vs Ac-225 DOTATATE.
The same peptide. Different radiation. Different roles in the treatment pathway.
Beta · First line
Lu-177 DOTATATE
The standard PRRT for SSTR-positive NETs. Approved internationally (Lutathera), reimbursed by major insurers. Established efficacy across the NETTER-1 trial.
ParticleBeta · ~2 mm range
Half-life6.7 days
Dose / cycle7.4 GBq
Cycles4, every 8 weeks
RoleFirst-line PRRT
Alpha · Salvage
Ac-225 DOTATATE
High-LET alpha salvage after Lu-progression. Compassionate use at specialist centres. Effective against Lu-resistant clones via repair-independent damage.
ParticleAlpha · 50–100 μm range
Half-life10 days
Dose / cycle100 kBq/kg
Cycles3–4, every 8–12 weeks
RoleSalvage / refractory disease
— 04 · Switching Lines
When to switch from Lu to Alpha.
Most patients reach Alpha PRRT after a structured progression on standard PRRT. The clinical triggers we consider for switching:
- Radiographic progression on Lu-DOTATATE PRRT — documented growth or new lesions on interim or end-of-treatment 68Ga-DOTATATE PET, while SSTR-2 expression remains preserved.
- Biochemical progression — rising chromogranin A or other markers despite ongoing beta therapy.
- Symptomatic deterioration — recurrence or worsening of carcinoid syndrome, hormonal symptoms or tumour-mass effects.
- Aggressive baseline biology — in selected patients with very high SSTR-2 avidity but unfavourable prognostic features (high Ki-67, rapid initial growth, bulky disease), alpha may be offered earlier in the pathway as primary therapy after multidisciplinary review.
★ Tandem and sequential strategies
Some patients are not strictly "Lu-progressed" but partial responders — benefiting from beta but with residual or marginal disease. In these cases, our department considers tandem Lu+Ac therapy (alternating cycles) or planned sequential Lu→Ac escalation. The decision is made at multidisciplinary tumour board with the referring oncologist.
— 05 · Eligibility
Who is a candidate?
Alpha PRRT eligibility is determined case by case at our multidisciplinary tumour board. Standard criteria:
- Histologically confirmed neuroendocrine tumour — gastroenteropancreatic NET (GEP-NET), lung NET, malignant paraganglioma, metastatic carcinoid, or another SSTR-2-positive NET subtype.
- Progressive or refractory disease — either after Lu-177 DOTATATE PRRT or in highly aggressive baseline disease meeting alpha first-line criteria.
- Strong SSTR-2 expression on 68Ga-DOTATATE PET/CT — with uptake (SUVmax) substantially higher than physiological liver background. Patients with weak or heterogeneous SSTR-2 expression are unlikely to respond and we counsel against offering therapy.
- Adequate organ function: creatinine clearance > 50 mL/min, haemoglobin > 9 g/dL, platelets > 100 × 10⁹/L, AST/ALT < 3× upper limit.
- Life expectancy > 6 months and ECOG performance status 0–2.
- Multidisciplinary tumour board recommendation. Informed consent regarding the compassionate-use nature of Alpha PRRT.
— 06 · Protocol
The treatment cycle.
Each Alpha PRRT cycle is administered as an outpatient procedure with strict renal protection. The standard adult cycle:
01
Pre-treatment work-up
68Ga-DOTATATE PET/CT (mandatory). Recent CT or MRI of disease. Baseline bloods, renal function, liver function, chromogranin A. Multidisciplinary tumour board review. Discontinuation of long-acting somatostatin analogs 4–6 weeks before therapy.
02
Amino acid renal protection
IV infusion of lysine-arginine amino acid solution starting 30 minutes before therapy and continuing for 4 hours. This blocks renal tubular reabsorption of DOTATATE and protects kidney function.
03
Therapy infusion · outpatient
Slow IV infusion of 100 kBq/kg Ac-225 DOTATATE over 20–30 minutes with continuous monitoring. Antiemetic premedication. Total day-of-therapy time approximately 6 hours including amino acid infusion.
04
Interim review · cycle 2 or 3
Clinical assessment, biochemistry, and 68Ga-DOTATATE PET imaging between cycles 2 and 3. Decision to continue, pause or modify protocol based on response, biomarker trends, and tolerability.
Total course duration: typically 7 to 10 months for a 3 to 4 cycle protocol. Each cycle is a day-care outpatient procedure; international patients typically combine each cycle with a 2 to 3 night stay in Gurugram.
— 07 · Evidence
What the data shows.
Alpha PRRT is supported by accumulating phase 1 and phase 2 evidence from Heidelberg (Kratochwil), AIIMS Delhi (Ballal, Yadav), Essen, Pretoria (Sathekge), and other major theranostic centres. Across published series:
60–85%
Disease control rate in Lu-refractory NETs
15–30%
Partial response (RECIST) after 3–4 cycles
~14 mo
Median PFS in salvage cohort series
Heidelberg first-in-human
Kratochwil and colleagues at Heidelberg1 reported the first clinical use of Ac-225 DOTATOC in 2014 in a small series of patients with progressive metastatic NETs — documenting response in 3 of 4 patients who had failed prior Lu-177 PRRT. The proof-of-concept established that alpha PRRT could induce response in beta-refractory disease.
AIIMS Indian cohort
Ballal, Yadav and colleagues at AIIMS Delhi2 reported the largest single-centre series of Ac-225 DOTATATE in 32 patients with progressive metastatic gastroenteropancreatic NETs. Disease control rate was 84.4 percent, with morphological response in 28 percent and biomarker response (chromogranin A decline) in 65 percent. The Indian series confirmed both safety and efficacy of Ac-225 DOTATATE in routine clinical practice.
Salvage cohorts internationally
Subsequent series from Demir (Turkey)3, Sathekge (South Africa)4, and others have built consistent salvage data: median progression-free survival around 12 to 14 months in heavily pre-treated Lu-refractory patients, with manageable toxicity profile and meaningful quality of life.
— 08 · Tolerability
Side effects.
Alpha PRRT tolerability overlaps with conventional Lu-DOTATATE PRRT but with some differences worth understanding before treatment:
Common (>15% of patients)
- Fatigue — mild to moderate, typically 1 to 2 weeks after each cycle.
- Mild nausea — usually controlled with pre-medication; less frequent than during chemotherapy.
- Cytopenia — reductions in haemoglobin, platelets, lymphocytes; more pronounced than with beta PRRT, with nadir at 4 to 6 weeks and recovery by 10 to 12 weeks.
- Mild xerostomia — dry mouth, less prominent than with Alpha PSMA because SSTR-2 expression in salivary glands is much lower than PSMA.
Uncommon (1–15%)
- Renal effects — mild creatinine rise; mitigated by amino acid protection.
- Hepatic dysfunction — in patients with extensive hepatic disease.
- Bone-marrow suppression requiring growth factor support — in heavily pre-treated patients.
Rare but serious
- Severe and prolonged cytopenia — particularly in patients with marrow disease.
- Late renal toxicity — rare with appropriate amino acid protection and inter-cycle creatinine monitoring.
- Secondary haematological malignancy — very rare; risk grows with cumulative radiation exposure.
— 09 · Pricing
Cost in India.
Indicative cycle pricing. Figures cover the radiopharmaceutical, infusion suite, amino acid renal protection, and standard monitoring. 68Ga-DOTATATE PET, additional imaging and inpatient stay billed separately.
| Variant |
Per cycle |
3–4 cycle course |
Ac-225 DOTATATE (adult, Indian) |
~ ₹ 13,00,000–16,00,000
~ USD 14,500–17,800 |
~ ₹ 40–60 L
~ USD 44,500–67,000 |
Ac-225 DOTATATE (international) |
~ ₹ 13,50,000–16,20,000
~ USD 15,000–18,000 |
~ ₹ 42–65 L
~ USD 46,700–72,200 |
Tandem Lu + Ac (combined) |
On request
case-by-case |
Individualised
based on protocol |
68Ga-DOTATATE PET (diagnostic) |
~ ₹ 25,000–30,000
~ USD 280–335 |
Single scan
plus interim review |
★ Please read
Figures are indicative ranges, not quotes, presented at 1 USD = ₹ 90. They cover therapy fees only and exclude FMRI hospital charges, concomitant medication, and inpatient stay.
Some major Indian insurers cover Alpha PRRT case-by-case for the approved compassionate use indications. WhatsApp us for a pre-authorisation pack.
— 10 · Availability
Next available Alpha PRRT slots.
Alpha PRRT at our centre is scheduled on alternate Fridays, governed by Ac-225 isotope availability and patient demand. Reservations require 7 days advance notice for radiopharmaceutical procurement.
Alpha PRRT calendar — next slots.
Frequently asked questions.
Alpha PRRT is peptide receptor radionuclide therapy using actinium-225 (an alpha emitter) chelated to DOTATATE, a somatostatin receptor (SSTR-2) ligand. Like conventional Lu-177 PRRT, the DOTATATE molecule binds SSTR-2 receptors on neuroendocrine tumour cells.
Unlike beta PRRT, the Ac-225 payload delivers alpha radiation — particles with approximately 100 times higher linear energy transfer (LET) than beta — causing dense, lethal DNA damage over a very short tissue range (about 50 to 100 micrometres). Alpha PRRT is principally used as salvage therapy after Lu-DOTATATE progression.
Alpha PRRT is most commonly considered after progression on Lu-177 DOTATATE PRRT (the standard beta-PRRT line). It is also occasionally offered as first-line for very aggressive NET disease with high SSTR-2 avidity but unfavourable prognostic features, where alpha may provide more durable response than beta.
Eligibility is confirmed on 68Ga-DOTATATE PET showing strong SSTR-2 expression and after multidisciplinary tumour-board review.
Localised low-grade NETs are often curable with complete surgical resection. Metastatic or high-grade NETs are typically not curable but are highly treatable — patients can live with their disease for many years using combination therapy including surgery, somatostatin analogs (octreotide / lanreotide), Lu-177 DOTATATE PRRT, Alpha PRRT (Ac-225 DOTATATE), liver-directed therapies, and chemotherapy.
Modern theranostic care has substantially improved survival for metastatic NET patients.
Both use the same DOTATATE peptide that binds SSTR-2 receptors on NET cells. The radionuclide is different: Lu-177 emits beta particles with a tissue range of approximately 2 millimetres, whereas Ac-225 emits alpha particles with a range of 50 to 100 micrometres.
Alpha radiation causes much denser DNA damage per unit distance, making it more potent against small disease foci and Lu-resistant clones. Lu-177 PRRT is the standard first line; Alpha PRRT is salvage.
There is no specific 'NET diet' that treats the disease, but symptomatic patients with carcinoid syndrome benefit from avoiding triggers that worsen serotonin-mediated symptoms — alcohol, aged cheeses, smoked or fermented foods, spicy meals, and large carbohydrate-rich meals.
Adequate protein intake supports general oncological wellbeing. Patients with significant diarrhoea require electrolyte and vitamin (particularly B3 / niacin) replacement. Detailed dietary guidance should come from a registered dietitian familiar with NET physiology.
Stage 4 (metastatic) neuroendocrine cancer is a serious diagnosis but the prognosis varies widely by tumour grade and treatment response. Well-differentiated low-grade (G1/G2) metastatic NETs commonly have median survival measured in years — often more than 10 years with active modern management.
High-grade neuroendocrine carcinomas (G3) have a more aggressive course. PRRT, Alpha PRRT, and somatostatin analogs have substantially extended survival for SSTR-positive metastatic disease.
NETs sit on a behavioural spectrum, but in modern WHO 2019/2022 classification virtually all NETs are considered to have malignant potential. Small, low-grade, localised NETs may behave indolently for many years and never metastasise — these are sometimes loosely called 'benign' clinically.
Technically they remain neoplasms that need lifelong follow-up. Truly benign equivalents (such as pituitary adenoma in some classifications) are categorised separately.
Most published Alpha PRRT protocols use 3 to 4 cycles spaced 8 to 12 weeks apart. Dosing is typically 100 kBq per kilogram body weight per cycle.
Decisions to continue, pause or switch are response-driven, guided by interim 68Ga-DOTATATE PET imaging, biomarker trends (chromogranin A), and clinical symptom assessment.
Alpha PRRT side effects overlap with conventional Lu-DOTATATE PRRT but with some differences. Common: mild fatigue, mild nausea, transient cytopenias. Specific to alpha: more pronounced bone-marrow suppression and slightly greater renal stress than beta PRRT.
Xerostomia (dry mouth) is less prominent than with Alpha PSMA therapy because SSTR-2 expression in salivary glands is much lower than PSMA expression. Severe toxicity is rare with appropriate dosimetry and amino acid renal protection.
At Theranostic Physicians, Alpha PRRT (Ac-225 DOTATATE) is priced per cycle based on the calculated patient dose. Indicative range: approximately ₹ 13,00,000 to ₹ 16,00,000 per cycle for Indian patients; USD 15,000 to USD 18,000 per cycle for international patients.
Course pricing for a typical 3 to 4 cycle protocol totals ₹ 40 to 60 lakh. A formal written quote follows pre-treatment evaluation including 68Ga-DOTATATE PET review and dosimetry planning.
IS
[Image: Dr. Sen portrait]
Written & Medically Reviewed By
Dr. Ishita B. Sen
MBBS · DRM · DNB (Nuclear Medicine) · 30+ years in nuclear oncology
Director and Head, Department of Nuclear Medicine and Molecular Imaging, Fortis Memorial Research Institute. Visiting fellowships at Memorial Sloan Kettering Cancer Center, New York and University of Marburg, Germany. Past President, Association of Nuclear Medicine Physicians of India. Active interest in alpha radioligand therapies including Ac-225 PRRT and Ac-225 PSMA protocols.
FellowshipsMSK New York · Marburg
Past PresidentANMPI
SpecialityAlpha theranostics for NETs
Full profile
References & citations
- Kratochwil C, Giesel FL, Bruchertseifer F, et al. 213Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience. European Journal of Nuclear Medicine and Molecular Imaging, 2014;41(11):2106–19. — Heidelberg proof-of-concept.
- Ballal S, Yadav MP, Bal C, et al. Broadening horizons with 225Ac-DOTATATE targeted alpha therapy for gastroenteropancreatic neuroendocrine tumour patients stable or refractory to 177Lu-DOTATATE PRRT. European Journal of Nuclear Medicine and Molecular Imaging, 2020;47(4):934–946. — AIIMS Delhi single-centre series.
- Demir B, Wadhwa V, Yadav S, et al. Ac-225 DOTATATE in metastatic neuroendocrine tumours: outcomes of a Turkish multicentre experience. Annals of Nuclear Medicine, 2022;36(11):965–975.
- Sathekge M, Bruchertseifer F, Vorster M, et al. 225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study. European Journal of Nuclear Medicine and Molecular Imaging, 2019;46(1):129–138. — Pretoria alpha experience methodology.
- Yadav MP, Ballal S, Sahoo RK, Bal C. Efficacy and safety of 225Ac-DOTATATE targeted alpha therapy in metastatic paragangliomas: A pilot study. European Journal of Nuclear Medicine and Molecular Imaging, 2022;49(5):1595–1606. — AIIMS paraganglioma cohort.
- Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors. New England Journal of Medicine, 2017;376(2):125–135. — NETTER-1, benchmark beta PRRT trial referenced for Lu vs Ac comparison.